Daiichi Sankyo Company, Limited
4568
Κατάταξη σε μετοχές
#729
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Τιμή μετοχής
$18.01
Κεφαλαιοποίηση
$32.77B
Αλλαγή (1 ημέρα)
0.14%
Αλλαγή (1 έτος)
-30.22%
Χώρα
JP
Εμπόριο Daiichi Sankyo Company, Limited (4568)
Κατηγορία
Healthcare
Κέρδη για την Daiichi Sankyo Company, Limited (4568)
Κέρδη τον 2026 TTM: 0
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Daiichi Sankyo Company, Limited, τα τρέχοντα κέρδη της εταιρείας είναι 0. Το 2026, η εταιρεία παρουσίασε κέρδη 0, ίσο με των κερδών του 2026 που ήταν 0. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Daiichi Sankyo Company, Limited από 2001 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2025 | $2.37B | 51.37% |
| 2024 | $1.57B | 64.03% |
| 2023 | $955.55M | 58.54% |
| 2022 | $602.72M | -9.73% |
| 2021 | $667.72M | -49.15% |
| 2020 | $1.31B | 69.80% |
| 2019 | $773.25M | 1.40% |
| 2018 | $762.56M | -3.25% |
| 2017 | $788.16M | -27.54% |
| 2016 | $1.09B | 63.21% |
| 2015 | $666.47M | -39.14% |
| 2014 | $1.10B | 7.65% |
| 2013 | $1.02B | 148.85% |
| 2012 | $408.79M | -71.86% |
| 2011 | $1.45B | 39.41% |
| 2010 | $1.04B | -133.26% |
| 2009 | $-3.13B | -287.21% |
| 2008 | $1.67B | 55.54% |
| 2007 | $1.08B | -7.55% |
| 2006 | $1.16B | 60.36% |
| 2005 | $725.65M | -8.51% |
| 2004 | $793.11M | 29.61% |
| 2003 | $611.93M | 0.45% |
| 2002 | $609.17M | -8.18% |
| 2001 | $663.43M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
